One‑Time Gene Editing Could Offer Decades of Cholesterol Control, Yet Safety Concerns Persist

A single therapeutic intervention could maintain cholesterol levels for decades, possibly eliminating the need for ongoing medication. Recent advances in gene editing bring this prospect nearer, yet researchers caution that the same technology also introduces significant safety, permanence, and unintended consequence concerns.

Gene therapy is currently employed to treat several serious diseases. These approaches can deliver functional gene copies, suppress harmful genetic activity, or directly edit DNA. Unlike traditional drugs that require repeated dosing, certain genetic therapies are engineered for a single administration.

Over 6,000 rare genetic disorders have been catalogued, but only a minority currently possess actionable targets for therapy. Gene therapies have already yielded notable successes for diseases such as spinal muscular atrophy and sickle cell disease.

Researchers are now investigating whether comparable strategies could prevent or manage broader common conditions, including hypercholesterolemia, cardiovascular disease, obesity, and diabetes.

This raises a fundamental question: Given that scientists can permanently alter genetic activity, should they proceed?

In a perspective published in the JAMA Internal Medicine, cardiologists Eric D. Smith, M.D., and Venkatesh L. Murthy, M.D., Ph.D., from the University of Michigan Health Frankel Cardiovascular Center outline how clinicians and researchers should balance the potential benefits of genomic therapies with their risks.

The two researchers explain why these therapies are promising, how they differ from conventional medicines, and what steps are required before they can be safely offered to millions.

Why One-Time Gene Therapy Is Different From Daily Medication

A key advantage of gene therapy is its potential to deliver durable results without repeated treatments.

Conventional medications rely on ongoing patient adherence, whereas genomic therapies target genetic material directly. They can supply a functional gene copy, inhibit a harmful gene, or edit a specific DNA sequence.

This enables the development of therapies designed for a single dose, commonly referred to as “one‑and‑done” treatments.

Nevertheless, a single administration does not guarantee lifelong efficacy.

Smith notes that many gene therapies employ engineered viruses to deliver genetic instructions into cells. The immune system may recognize these vectors and mount a response, making re‑administration challenging or impossible, even if the initial benefits wane.

Another important distinction concerns which cells are changed. Current gene therapies generally target somatic cells, which are the body’s cells other than those involved in reproduction. Unlike germline editing, these treatments are not intended to create genetic changes that can be inherited by future generations.

Why Gene Editing Common Diseases Raises New Risks

For individuals with rare, severe genetic disorders, the potential benefits of gene therapy often outweigh the possible risks. Many patients have limited therapeutic options, rendering experimental interventions appealing.

The complexity increases when the same technology is applied to common diseases.

Conditions such as hypercholesterolemia, cardiovascular disease, obesity, and diabetes already have established therapies. Many of these medications can be adjusted as a patient’s condition evolves or discontinued if adverse effects arise.

A permanent genetic intervention may lack the flexibility to adjust dosage or discontinue treatment.

Murthy also highlights a major concern: the potential number of recipients. A rare serious side effect could affect a substantial patient population if the therapy is administered to millions.

Consequently, therapies intended for broad use must meet especially rigorous safety standards.

Five Questions Scientists Say Must Be Answered

To determine the appropriateness of genomic therapy, Smith and Murthy propose evaluating five essential factors:

1. Disease severity: How severe is the condition, and what potential benefit could patients receive?
2. Existing treatments: Are there already effective therapies that can be modified or withdrawn as needed?
3. Treatment durability: Is the target tissue appropriate for an intervention designed to provide durable results after a single dose?
4. Delivery risks: Are the delivery risks acceptable relative to the disease’s severity?
5. Long-term monitoring: Can researchers reliably monitor safety and effectiveness over many years, especially with large patient numbers?

The final question may prove especially challenging.

Clinical trials typically enroll relatively small patient groups and monitor them for limited periods. While they can identify many safety concerns, they may overlook extremely rare complications or issues that emerge only after prolonged use.

Some adverse effects may only become evident once a treatment has been administered to a much larger population.

The Problem of Tracking Risks That Could Emerge Years Later

Smith contends that long‑term monitoring must be integral to the introduction of gene therapies into clinical practice, not an afterthought.

Patient registries, which collect data on individuals receiving specific treatments, have already demonstrated the value of extended follow‑up.

Therapies that may eventually serve millions of patients will demand monitoring systems capable of handling vastly larger scales.

These systems must be independent and standardized to allow researchers to consistently assess treatment efficacy and detect unexpected health issues over time.

Without reliable long‑term data, physicians may struggle to fully understand the consequences of genetic interventions that are difficult to reverse.

The Million-Dollar Challenge Facing Gene Therapy

Safety is not the sole barrier to mainstream healthcare adoption of gene editing; cost also plays a decisive role in its availability.

Some existing gene therapies carry list prices exceeding $1 million per patient, with several costing considerably more.

These prices may be deemed justifiable for certain rare, life‑threatening conditions, especially when few alternative treatments exist.

Applying comparable pricing to diseases affecting millions would impose enormous financial pressure on healthcare systems.

Smith and Murthy argue that affordability and access must be included in the discussion from the outset.

Even a highly effective gene therapy could exacerbate healthcare inequalities if only a minority of patients can access it. Researchers and policymakers must consider not only efficacy but also equitable delivery to avoid worsening existing disparities.

Could One Gene-Editing Treatment Prevent Heart Disease for Decades?

Despite these challenges, the prospect of using gene editing to prevent common diseases is becoming increasingly realistic.

Researchers are already conducting early studies to determine whether a single genetic treatment can produce sustained reductions in LDL, commonly termed “bad” cholesterol.

LDL cholesterol promotes the accumulation of fatty deposits within arteries, raising the risk of heart attacks and other cardiovascular events. Long‑term LDL reduction is a key strategy for mitigating cardiovascular risk.

If gene editing can safely achieve sustained reductions, it could eventually provide a novel approach to cardiovascular protection without the need for indefinite medication.

However, promising early results alone will not suffice to justify widespread adoption.

Before these therapies become routine options for common conditions, researchers will need compelling evidence that their benefits endure, their risks remain acceptably low over many years, and their costs are manageable. Robust safeguards will also be essential.

For Smith and Murthy, the aim is not to impede genetic medicine but to ensure that a technology with transformative potential is introduced carefully and responsibly.

As gene therapy expands from rare disorders to conditions affecting millions, the central challenge will be ensuring that the promise of lasting protection does not compromise long‑term patient safety.

Source link